Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,771 Shares

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the completion of the sale, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Enfusion Stock Down 3.1 %

Shares of NYSE ENFN opened at $9.97 on Friday. Enfusion, Inc. has a 52-week low of $7.52 and a 52-week high of $11.38. The stock has a market capitalization of $1.28 billion, a P/E ratio of 249.31, a P/E/G ratio of 3.98 and a beta of 0.95. The firm’s 50-day moving average price is $10.11 and its two-hundred day moving average price is $9.19.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ENFN shares. Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Piper Sandler boosted their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.25.

Institutional Investors Weigh In On Enfusion

A number of hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System acquired a new stake in Enfusion in the 2nd quarter valued at approximately $86,000. Harbor Capital Advisors Inc. raised its holdings in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares in the last quarter. Belvedere Trading LLC acquired a new stake in shares of Enfusion during the 3rd quarter valued at $114,000. Paloma Partners Management Co purchased a new position in Enfusion in the 3rd quarter worth about $157,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Enfusion by 27.7% during the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after acquiring an additional 4,239 shares during the period. 81.05% of the stock is currently owned by institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.